Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a solid tumour cancer that has been confirmed by a medical test (not small cell lung cancer or germ cell tumour)
- You are reasonably active and able to carry out daily activities, as measured by a standard health scale (confirm with trial site)
- You have between 1 and 10 cancer spots that have spread to the brain, with no more than two of those spots being 3 cm or larger in size
- The largest brain tumour spot or surgical removal site measures no more than 6 cm across
- Your kidneys are functioning well enough, based on blood test results (confirm with trial site)
- You are in good enough general health and emotional wellbeing to complete all parts of the study, including memory and thinking tests at set points during the trial
- If you are a woman who could become pregnant, you have had a negative pregnancy test within the last 21 days before joining
- If you are a woman who could become pregnant, or a man, you must agree to use reliable contraception during the study and for 4 months after the last treatment
- You are able to give your own written consent to take part and can speak English
Who may not be able to join:
- You have been diagnosed with a brain tumour that started in the brain, such as a glioma or other primary brain tumour
- You have had brain surgery within the last 14 days
- You are planned to receive chemotherapy at the same time as the radiation treatment used in this trial
- The cancer has spread to the lining around the brain or spinal cord
- You are having more than one seizure per week despite taking seizure medication, and this has been happening for the past 2 months
- You are currently pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wenyin Shi, MD, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phone: (215) 955-6702
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Neurocognitive function as measured by neurocognitive decline on a battery of tests
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.